Harrow, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) approved its transitional pass-through application for TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL. This approval, effective April 1, 2025, and lasting for three years, makes TRIESENCE eligible for separate reimbursement outside of the surgical bundled payment in both Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings.
TRIESENCE is now the only preservative-free synthetic corticosteroid with separate reimbursement in all traditional settings of care, including eyecare professional offices, ASCs, and HOPDs. CMS will reimburse TRIESENCE at the Average Sales Price (ASP) plus 6% in ASC and HOPD settings, enhancing its financial attractiveness for providers.
Mark L. Baum, Chairman and CEO of Harrow, stated that this decision expands patient access to TRIESENCE, allowing ophthalmologists to confidently use the FDA-approved, preservative-free treatment. This regulatory milestone is expected to improve surgical outcomes and patient safety across the country by facilitating the use of TRIESENCE over off-label alternatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.